Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
| 07-2016 | 06-2016 | 04-2016 | 03-2016 | 01-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,437 | -13,956 | N/A | -6,607 | -6,255 |
| Depreciation Amortization | 8 | 117 | N/A | 41 | 26 |
| Accounts payable and accrued liabilities | 996 | -1,273 | N/A | -272 | -203 |
| Other Working Capital | -835 | -430 | N/A | -381 | -2,325 |
| Other Operating Activity | -2,386 | 3,198 | 0 | 2,135 | -2,011 |
| Operating Cash Flow | $-5,654 | $-12,344 | $N/A | $-5,084 | $-10,768 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -43 | -62 | N/A | -184 | -9 |
| Investing Cash Flow | $-43 | $-62 | $N/A | $-184 | $-9 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 2 | N/A | 0 | N/A |
| Other Financing Activity | 0 | -4,500 | 0 | 0 | 33,002 |
| Financing Cash Flow | $N/A | $-4,498 | $N/A | $N/A | $33,002 |
| Exchange Rate Effect | -440 | N/A | N/A | N/A | -583 |
| Beginning Cash Position | 21,764 | 53,723 | N/A | 53,723 | 2,526 |
| End Cash Position | 15,627 | 36,819 | N/A | 48,455 | 24,168 |
| Net Cash Flow | $-6,137 | $-16,904 | $N/A | $-5,268 | $21,642 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,654 | -12,344 | N/A | -5,084 | -10,768 |
| Capital Expenditure | -43 | -245 | N/A | -184 | -9 |
| Free Cash Flow | -5,697 | -12,589 | 0 | -5,268 | -10,777 |